Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 6—June 2022
Dispatch

Outbreak of Imported Seventh Pandemic Vibrio cholerae O1 El Tor, Algeria, 2018

Nabila BenamroucheComments to Author , Chafika Belkader, Elisabeth Njamkepo, Sarah Sihem Zemam, Soraya Sadat, Karima Saighi, Dalila Torkia Boutabba, Faiza Mechouet, Rym Benhadj-Slimani, Fatma-Zohra Zmit, Jean Rauzier, Farid Kias, Souad Zouagui, Corinne Ruckly, Mohamed Yousfi, Amel Zertal, Ramdane Chouikrat, Marie-Laure Quilici, and François-Xavier WeillComments to Author 
Author affiliations: Institut Pasteur d’Algérie, Algiers, Algeria (N. Benamrouche, C. Belkader, S.S. Zemam, S. Sadat, D.T. Boutabba, R. Benhadj-Slimani, F. Kias); University of Algiers I, Algiers (N. Benamrouche, F. Mechouet, F.-Z. Zmit, A. Zertal); Institut Pasteur, Université Paris Cité, Paris, France (E. Njamkepo, J. Rauzier, C. Ruckly, M.-L. Quilici, F.-X. Weill); Public Hospital Establishment of Boufarik, Blida, Algeria (K. Saighi, M. Yousfi, R. Chouikrat); Specialized Hospital Establishment El Hadi Flici, Algiers (F. Mechouet, F.-Z. Zmit, A. Zertal); University Hospital of Oran and University of Oran I, Oran, Algeria (S. Zouagui)

Main Article

Table

Characteristics of Vibrio cholera 01 epidemic strain, Algeria, 2018*

Category Strain characteristic
Serogroup, serotype, biotype O1, Ogawa, El Tor
Genomic wave 3
Sublineage Seventh pandemic V. cholerae O1 biotype El Tor
Genetic markers
 ctxB7, tcpACIRS101, VSP-IIć
AMR profile, antimicrobial drug (MIC)†
Streptomycin (64–128 mg/L) Resistant
Sulfamethoxazole (1,024 mg/L) Resistant
Trimethoprim/sulfamethoxazole (32 mg/L) Resistant
Trimethoprim (32 mg/L) Resistant
Chloramphenicol (16 mg/L) Intermediate
Nalidixic acid (256 mg/L) Resistant
Ciprofloxacin (0.25 mg/L) Decreased susceptibility
Nitrofurantoin (64 mg/L) Intermediate
Colistin (2 mg/L)
 Susceptible
Horizontally acquired AMR elements ICEVchInd5
Horizontally acquired AMR genes
 strAB, floR, sul2, dfrA1
Chromosomal gene mutations, AMR phenotype
gyrA_S83I and parC_S85L Resistance to nalidixic acid; decreased susceptibility to ciprofloxacin
nfsA_R169C and nfsB_Q5Stop Intermediate susceptibility to nitrofurantoin
vprA_D89N Susceptibility to colistin

*Data were collected from 20 sequenced outbreak isolates. AMR, antimicrobial resistance; ICEVchInd5, integrative conjugative element of the SXT/R391 family; VSP-IIΔ, deletion in Vibrio seventh pandemic island II. †MICs according to Clinical and Laboratory Standards Institute (https://clsi.org/media/1450/m45ed3_sample.pdf). ‡Deletion encompassing VC_0495-0512 according to GenBank accession no. AE003852.

Main Article

Page created: March 23, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external